Public Release: 

Insilico to present at the 2019 World Medical Innovation Forum

InSilico Medicine, Inc.

IMAGE

IMAGE: Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico Medicine, will present at the 2019 World Medical Innovation Forum in Boston, April 8-10, 2019. view more 

Credit: Insilico Medicine

Tuesday, March 5, 2019 - Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest advances in Artificial Intelligence for Aging Research and Productive Longevity at the 2019 World Medical Innovation Forum in the section titled "From Startup to Impact (Pharma and Diagnostics)" in Boston, on April 8.

Artificial Intelligence (AI) techniques, such as deep learning (DL) and reinforcement learning (RL) play a pivotal role in studying the biology of aging on many levels. The discussion will focus on the new frontiers in the biology of aging and the future of longevity science. Another major point of discussion is how technology and industry collaborations can drive successful outcomes in longevity science.

"We are happy to present our latest research at the 2019 World Medical Innovation Forum, which gathers the leading longevity leaders. The topic of AI for Aging research and Productive longevity is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area", said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.

"Dr. Alex Zhavoronkov is a board director of AAIH and among the leading proponents of AI innovation. His insights on the benefits and issues of AI will give attendees of the 2019 World Medical Innovation Forum a real world perspective on clinical applications", said Annastasiah Mudiwa Mhaka, PhD., president of the Alliance for Artificial Intelligence in Healthcare (AAIH).

The World Medical Innovation Forum will bring together global leaders in the emerging discipline of artificial intelligence and machine learning for in-depth conversations on the fast-developing novel technologies that characterize this early era of adoption. Impact on patients, clinicians and systems will be examined in depth. The Forum panels, consisting of industry and investment executives, teamed with Harvard clinical and research leaders, will focus on patient interactions across care settings, and the role technology and data can play in advancing knowledge discovery and care delivery.

###

Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.

For further information, images or interviews, please contact:

Contact: Polina Firsanova
ai@pharma.ai Website: http://insilico.com/

Conference Official Website : https://worldmedicalinnovation.org/

About Insilico Medicine, Inc

Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. http://www.insilico.com

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.